Tag Archive for: opthalmology

Breye Therapeutics Commences Oral Dosing of Danegaptide in Patients with Diabetic Retinopathy

Investigating potential for an oral treatment in diabetic retinopathy First patient dosed in Phase 1b/2a clinical trial Copenhagen, Denmark, 25 January 2024 – Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, today announces the start of a phase 1b/2a clinical trial to investigate danegaptide, following oral administration, […]

Novo Holdings and Sound Bioventures launch Breye Therapeutics to develop novel oral therapies for ophthalmologic diseases

Industry expert Ulrik Mouritzen M.D. appointed Chief Executive Officer Funding to advance lead asset to phase 1b clinical trial and further build pipeline COPENHAGEN, Denmark, Nov. 10, 2022 /PRNewswire/ — Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, today announces it has emerged from stealth after closing a seed financing of EUR […]